Abstract
Introduction: The ACT-II trial confirmed mitomycin C with 5-FU as the standard of care for anal cancer when combined with conventionally planned radiotherapy. Capecitabine is widely used as an oral alternative to 5-FU in gastrointestinal cancer with encouraging preliminary results for anal cancer. Modern radiotherapy techniques allow greater dose shaping than with fields selected on the basis of macroscopic disease and bony anatomy. We sought to assess the toxicity and efficacy of a new regime using mitomycin C with capecitabine and conformally planned radiotherapy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical oncology (Royal College of Radiologists (Great Britain))
Paper Title
Journal
Date
